Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.38 |
| ▸ | PLK1 | P53350 | 2/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294888 | 0.90 | IRAK4 (0.33) | IRAK4PLK1PLK2ROCK1 | |
| SCHEMBL3297350 | 0.89 | ROCK1 (0.38) | IRAK4ROCK1 | |
| SCHEMBL3298897 | 0.88 | IRAK4 (0.31) | IRAK4 | |
| SCHEMBL3305414 | 0.87 | ROCK1 (0.37) | IRAK4ROCK1 | |
| SCHEMBL3305435 | 0.87 | ROCK1 (0.37) | IRAK4ROCK1 | |
| SCHEMBL3294739 | 0.87 | SCN2B (0.36) | MAPK14 | |
| SCHEMBL3303924 | 0.86 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL3300992 | 0.85 | ROCK1 (0.33) | IRAK4PLK1PLK2ROCK1 | |
| SCHEMBL3301125 | 0.85 | ROCK1 (0.34) | IRAK4ROCK1 | |
| SCHEMBL3298201 | 0.84 | SMN1; SMN2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | HPGDS 3156/4885IRAK4 2516/4885PLK1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.